Lilly's Lechleiter dons chairman's title

Eli Lilly has named CEO John Lechleiter to the additional post of chairman of the board. Current Chairman Sidney Taurel is retiring at the end of this year.

Ranbaxy Laboratories, has retained former New York City mayor Rudy Guiliani to help it resolve an FDA ban on importing over 30 generic drugs.

Oriel Therapeutics has named Richard Fuller, M.D., a former senior executive at GlaxoSmithKline, CEO.

Aradigm has appointed Nancy Pecota as its new CFO.

US Oncology named Michael A. Sicuro as executive vice president and CFO.

Sofinnova Ventures named Lars Ekman, M.D., Ph.D., as an executive-in-residence.

Anna Ahlberg, Vitrolife's CFO for just over four years, has decided to terminate her employment at Vitrolife.

Michael Beckert has decided to resign as executive vice president and chief medical officer of Lifecycle Pharma to pursue other opportunities. Karin Hamberg will assume responsibility for clinical, regulatory, and medical affairs.

Incyte has appointed Patricia S. Andrews as executive vice president and chief commercial officer.

Lpath has appointed John Bender, Pharm.D., senior vice president of research and development.

Pulmatrix named John P. Hanrahan, M.D., as senior vice president and chief medical officer.

Amarin named Dr. Mehar S. Manku to the position of chief scientist.

Neotropix has named Anthony Williams, M.D., as its chief medical officer.

Halozyme Therapeutics announced that Douglas B. Muchmore, MD, has joined the company as vice president, endocrinology clinical development.

Codexis has named Lynn Marcus-Wyner, Ph.D., as vice president, intellectual property.

Curemark has named Dr. Elisa J. Zinberg as vice-president of operations.

ImmunoCellular Therapeutics has elected James G. Bender, Ph.D., M.P.H., to the position of vice president, clinical development.

Julie Anne Smith has been appointed as Enobia's vice president, chief commercial officer, and Jayant Aphale, PhD., MBA has been appointed as vice president, manufacturing and process sciences.

Protea Biosciences has appointed G. Reid Asbury, Ph.D., director of marketing.

Accelerated Community Oncology Research Network has named Tara Webb as senior director of business development.

Tengion has named Brian J. G. Pereira, M.D., to its board of directors.

Medimetriks Pharmaceuticals announced that Wolfgang Kunze has been added to its board of directors.

Molecular Insight Pharmaceuticals has added four people to its board. They are: David R. Epstein, Dr. Yvonne Greenstreet, Joseph M. Limber, and Dr. Anthony F. Martin.